Sector News

Could troubled Mylan swing a sale to private equity buyer? One analyst thinks so

September 24, 2018
Life sciences

When Mylan said last month that it would consider a sale, analysts were skeptical the company could find an interested buyer. But one of them is changing his tune.

On Friday, RBC Capital Markets analysts Randall Stanicky laid out the case for a private equity player completing a leveraged buyout of the generics leader. It’s a potential move he says “should not be dismissed” thanks to Mylan management’s frustration with the company’s stock price and a generics industry Stanicky thinks is on the up-and-up.

The way he sees it, years without any stock movement—Mylan’s shares have been flat for the last five—may convince the company’s leaders to go private. They’ve already signaled their impatience with U.S. markets that continue “to underappreciate and undervalue the durability, differentiation and strengths of Mylan’s global diversified business,” as Mylan put it in an August statement.

And the generics industry, which has been ravaged by pricing pressure in recent years, could be headed for a turnaround, he figures, which would make now a “favorable” time for a private equity suitor to strike.

Of course, there are some major hurdles—namely, that Mylan’s purchaser, even if prepared to take on a whole lot of debt, would have to put forth $11.6 billion in equity to pull off a deal of about $40 billion, according to Stanicky’s calculations. But while that’s a “large amount, there are plenty of examples of sizable LBOs to point to as support,” he noted.

Mylan first announced last month, amid a spate of bad earnings news, that it would launch a strategic review, keeping all options—including a sale—on the table. At the time, though, industry watchers didn’t get too jazzed about the possibility.

“Many at the time (including us) dismissed this as an attempt to support the stock amidst a sizable miss and guide cut,” Stanicky said.

Even if the generics landscape does improve, though, Mylan still has some of the same problems that made other analysts doubtful it could work out a sale—such as troubles at a Morgantown, West Virginia, manufacturing facility and what Bernstein’s Ronny Gal called slower-than-expected approvals and uptake for the company’s complex generics.

“The U.S. business has been hit twice—once by the broader industry trends” affecting generics makers and “then by company-specific action,” Gal wrote to clients at the time.

Wells Fargo’s David Maris agreed in his own investor note, writing that, “We do not think there is a high likelihood that a public or private buyer for the company or significant parts of the company emerges.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.